Life Sciences Marketing
In an industry where claims are rigorously scrutinized and skepticism is the default, trust is not a soft marketing requirement. It is a commercial prerequisite. Due to its paramount importance, I wanted to provide some examples of how some life sciences companies are building trust intentionally.
Marketing in Hard Trust Environments
Life sciences companies operate in one of the hardest trust environments in the world. Their audiences, investors, physicians, patients, regulators, and biopharma partners are trained to assess claims, demand evidence, and wait for proof before they commit. The bar is higher here than almost anywhere else in B2B. And it should be because a poor decision is not a mere inconvenience. It could mean life and death.
And yet invariably, companies that consistently build market visibility are not the ones with the strongest data packages. What sets them apart is their ability to turn data into something stakeholders can visualize and believe in while building credibility that compounds with every decision.
Trust Building Marketing Strategy
Below are six patterns drawn from across the life sciences sector that illustrate how trust-building, when treated as a strategic function rather than a communications afterthought, creates durable commercial advantage.
PATTERN 1
Storytelling as Strategic Infrastructure
For years, biotech marketing defaulted to what might be called data-overloaded communication: mechanism-of-action slides, efficacy tables, technical papers distributed through conference posters, and journal reprints. The audience received information. They rarely received a reason to believe.
A growing cohort of early- and growth-stage biotechs has made a different choice. Rather than leading with technology, they lead with the problem — and more specifically, with the people who live it.
Diagnosis, the uncertainty that follows, the search for answers, the experience of treatment. Patient journeys are humanized in a lived experience that a physician, investor, or patient advocate can locate themselves in the story.
Storytelling is not a soft skill in biotech. It is strategic infrastructure — the thing that de-risks perception, accelerates buy-in, and gives stakeholders something to believe in, not just something to analyze.
The commercial logic is clear. Investors make decisions under uncertainty. Physicians adopt new therapies based on experience and confidence as much as evidence. Patients ask for treatments they feel personally connected to. Human-centered narrative builds each of these forms of trust more efficiently than technical communication alone. It does not replace the evidence; it makes the evidence matter.
PATTERN 2
Case Studies as the Highest-Leverage Content Format
In B2B life sciences, few content formats earn the credibility that a well-constructed case study does. Research consistently places case studies among the most effective tools in the buyer journey because they provide real-world operational proof.
For biotech companies selling into complex, regulated environments, i.e., selling to hospital systems, biopharma partners, CROs, or clinical networks, abstract claims about capability carry limited weight. What they want is evidence that a company has done this before, under similar conditions, with verifiable outcomes.
Effective case studies share a consistent structure: a specific problem, a described approach, and quantified results. Quantification matters. Percentage reductions in cost-per-sample, improvements in turnaround time, and increases in assay sensitivity where concrete numbers transform testimonials into evidence. They also make case studies shareable within organizations, because a procurement lead or medical director can forward a number to a CFO in a way they cannot forward a general qualitative endorsement.
When I was a hospital sales rep, I sold many drugs, including Plavix, Zyprexa, Lantus, Avapro, Cardizem, etc. I can tell you that the most frustrating thing I heard from some doctors, after I had painstakingly showed superior efficacy, was, “Brad, that is not clinically relevant.” How do I respond to that? I cannot say that in my experience it certainly is. At that moment, I wished I had a case study to back up my claims.
Companies that invest in case study development early, before launch, during validation partnerships, while working with early-access customers, arrive at commercialization with a body of proof that shortens the sales cycle and reduces perceived risk for new buyers.
PATTERN 3
Visibility Built Through Specialized Partners: The Cocoon Bioscience Example
When Cocoon Bioscience, a biotech spinout manufacturing recombinant protein, needed to carve out its own identity in a crowded market, it faced a challenge common to many early-stage companies: the science was credible, but the market did not yet know who they were.
The company chose to partner with a marketing team that could genuinely understand and translate niche technical content. Rather than choosing a generalist agency using templates, they opted for specialists who could engage with the actual complexity of the product. The result was a complete brand and content overhaul built around Cocoon’s specific value proposition. It focused on the patient and the impact on their lives rather than the data.
The outcomes were measurable and significant: website users increased by 20 percent, LinkedIn followers grew by 184 percent, and organic search traffic rose by more than 4,000 percent following the launch of the new brand and content program.
Achieving trust was not incidental. Cocoon’s Head of Marketing explicitly described the agency relationship as one built on trust and confidence that their partners understood what the company wanted and could navigate industry and language barriers to execute it effectively. It was the marriage of science and marketing that set the expectations.
The broader lesson is about specialization and understanding the why and how of therapy and its impact on patients’ lives. Trust in biotech marketing is often built not just with external audiences, but through the operational trust between a company and the partners executing its strategy. When that partnership is strong, where the agency genuinely understands the science and the commercial context, the resulting content carries credibility that generalist work rarely understands and achieves.
PATTERN 4
Treating Compliance as a Trust Asset, not a Constraint
Pharmaceutical marketing operates under regulatory frameworks that many marketers deem as hurdles. The requirements of claims substantiation, medical-legal-regulatory review, and adverse-event reporting can feel like constraints on creative execution.
Companies that consistently outperform on trust treat compliance differently. They use it as a signal to their audiences. When a pharmaceutical brand invests in multi-channel disease education through provider resource hubs, real-time correction of misinformation, and transparent communication about clinical data, it sends a message about organizational character that promotional content cannot replicate.
Especially in vaccine markets and rare disease categories, this approach has measurable downstream effects. Campaigns built around genuine education, not product promotion, improve physician confidence and counteract vaccine hesitancy. They increase patient adherence. They build the kind of long-term engagement that crystallizes outcomes data and supports label extensions. Compliance, reframed, becomes a competitive advantage.
PATTERN 5
Community as Infrastructure: Vaccine and Rare Disease Models
Vaccine trust through transparency and partnership
Large-scale vaccine campaigns offer some of the most instructive examples of trust-building at a systemic level. Global health organizations working with vaccine manufacturers, including initiatives supported by the Serum Institute of India and the Bill and Melinda Gates Foundation, have built public confidence through three consistent mechanisms: early and honest communication about both benefits and risks, partnership with local health workers and community leaders, and real-time responsiveness to misinformation.
The combination matters. No single channel builds vaccine confidence in isolation. Trust is constructed at the intersection of institutional credibility, community-level relationships, and consistent factual communication. The lesson for biotech marketers is that trust in a product is inseparable from trust in the organization behind it and that organizational trust is built in the spaces between campaigns, not just during them.
Rare disease: the Cystic Fibrosis Foundation model
The Cystic Fibrosis Foundation offers what may be the most compelling case study of community-driven trust-enabling commercial outcomes in biotech. The Foundation did not wait to engage the CF community after a therapy was developed. It built and sustained that community for decades by funding research, supporting families, generating disease-state knowledge, and then used that trust infrastructure to accelerate drug development.
When the Foundation made an early-stage investment in Vertex Pharmaceuticals, it was not simply providing capital. It was building the community relationships, patient data, and clinical networks that helped bring Trikafta to the market, a therapy that now addresses the underlying disease mechanism for approximately 90% of CF patients. Community and commercial outcomes were intertwined.
Pre-approval community building
Increasingly, pharmaceutical and biotech companies are adapting this model for rare-disease launches more broadly. Platforms that enable and participate in condition-specific patient communities for disease-state education, trial recruitment, and patient feedback allow companies to build trust with their eventual customers long before a therapy is approved. By the time of launch, the audience already exists. Engagement is already established. The conversion from awareness to advocacy is shorter and more durable.
PATTERN 6
Patient Advocacy as a Formal Commercial Function: The Genentech Approach
Most biotech companies treat patient advocacy as a communications function and a channel for technical product messaging. Genentech has built it as a strategic function, with a dedicated Patient Advocacy Relations team maintaining formal relationships with more than 500 advocacy organizations across 50 disease areas.
The distinction matters. A communications function uses advocates to reach patients. A strategic function co-creates programs with advocates to understand patient needs, shape clinical development, and design support services. The outputs are different: materials that reflect real patient experience rather than brand messaging. These support programs solve actual real-life problems, and foster a level of community trust that promotional investments cannot replicate.
Industry guidance for rare disease marketers now consistently emphasizes advocacy co-creation, collaborative development of educational materials, support services, and events that center on diagnosis, treatment navigation, and the challenges of daily life.
The commercial returns are real. Advocacy organizations provide access to diagnosed patient populations, trial-ready participants, and the kind of institutional credibility that accelerates payer and physician acceptance. But the model only works when the engagement is genuine and when it is oriented around patient needs, not brand objectives. Trust, in this context, is not a marketing outcome. It is the mechanism through which commercial outcomes become possible.
What These Patterns Have in Common
The companies in these examples are not all large. They do not all have large marketing budgets. What they share is a particular orientation: they treat trust as infrastructure rather than outcome, and they invest in it continuously rather than episodically.
The technical elements of this approach are straightforward. Human-centered communication that connects science to patient experience. Documented case studies that convert capability claims into operational proof. Compliance frameworks that demonstrate organizational integrity rather than constrain creative work. Community relationships built before commercial considerations. Advocacy partnerships that co-create value rather than extract it.
The strategic insight underneath all of them is the same. In life sciences, the distance between a product and its market viability is not primarily a distribution challenge. It is a trust challenge. Companies that close that distance by demonstrating consistent understanding, reliability, and real-world value —do not just build better marketing, they build more durable businesses.
How BTS Health Supports Marketing Teams
BTS Consulting works with life sciences companies to build market visibility, stakeholder trust, and commercial positioning.
To discuss your organization’s communication strategy, contact us at BTShealth.com.
By Brad Saeed
Brad Saeed, MS, MBA, Founder, President, & Lead Strategist
Brad is the founder and president of BTS Consulting, a life sciences strategy and marketing firm he launched in 2009 to solve a gap he experienced firsthand. As a former decision science project leader, he saw that most external support teams were either fluent in science or strong in marketing, but rarely both. With a background in molecular and cell biology and formal training in business strategy, Brad set out to bridge the divide between scientific innovation and effective market execution.
With over 20 years of industry experience, he began his career at the bench and has since led high-impact initiatives across pharmaceuticals, diagnostics, medical devices, and healthcare services. Brad is a seasoned strategist and science-driven content developer known for driving market acceptance of complex technologies. He is also a skilled grant writer and a respected voice at the intersection of science, strategy, and commercialization.
